A novel cyclic peptide targeting LAG-3 for cancer immunotherapy by activating antigen-specific CD8+ T cell responses

• Autores principales: Wenjie Zhai (Autor), Xiuman Zhou (Autor), Hongfei Wang (Autor), Wanqiong Li (Autor), Guanyu Chen (Autor), Xinghua Sui (Autor), Guodong Li (Autor), Yuanming Qi (Autor), Yanfeng Gao (Autor)
• Formato: Libro
• Publicado: Elsevier, 2020-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

PD-1 and CTLA-4 antibodies offer great hope for cancer immunotherapy. However, many patients are incapable of responding to PD-1 and CTLA-4 blockade and show low response rates due to insufficient immune activation. The combination of checkpoint blockers has been proposed to increase the response ra...